Cubist Pharmaceuticals SVP Gregory Stea Sells 5,312 Shares (CBST)
Cubist Pharmaceuticals (NASDAQ:CBST) SVP Gregory Stea sold 5,312 shares of the company’s stock on the open market in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $74.90, for a total transaction of $397,868.80. Following the completion of the transaction, the senior vice president now directly owns 14,189 shares of the company’s stock, valued at approximately $1,062,756. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Jefferies Group raised their price target on shares of Cubist Pharmaceuticals from $82.00 to $85.00 in a research note to investors on Tuesday. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Cubist Pharmaceuticals in a research note to investors on Friday, December 27th. They now have a $70.00 price target on the stock. Finally, analysts at RBC Capital raised their price target on shares of Cubist Pharmaceuticals from $78.00 to $82.00 in a research note to investors on Friday, December 20th. They now have an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating, five have given a hold rating and eight have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $68.27.
Cubist Pharmaceuticals (NASDAQ:CBST) traded up 0.19% on Wednesday, hitting $74.91. 1,098,204 shares of the company’s stock traded hands. Cubist Pharmaceuticals has a 52-week low of $40.44 and a 52-week high of $74.80. The stock has a 50-day moving average of $67.05 and a 200-day moving average of $63.05. The company has a market cap of $5.548 billion and a P/E ratio of 194.21.
Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.